研究单位：[1]The First Affiliated Hospital of Guangzhou Medical University[2]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[3]Beijing Chao-yang Hospital, Capital Medical University,Beijing,Beijing,China[4]Songshan General Hospital,Chongqing,Chongqing,China[5]The First Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China[6]Henan Provincial People's Hospital,Zhengzhou,Henan,China[7]Tongji Hospital，Tongji Medical College of Hust,Wuhan,Hubei,China[8]West China Hospital of Sichuan University,Chengdu,Sichaun,China
This study was a multicenter, open, observational study and was divided into two stages; Stage I study includes patients with suspected asthma to observe the diagnostic value and safety of Methacholine Choline Provocation Test. All patients clinically evaluated for bronchial provocation testing were included in the stage II study to further validate the diagnostic value and cutoff value of the methacholine choline provocation test.
